Close Menu

p53

By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.

Investigators saw signs that risky TP53 missense mutations may interfere with wild type copies of the tumor suppressor gene in acute myeloid leukemia and other myeloid cancers.

The researchers found that background TP53 gene mutations increase with age and could affect efforts to develop liquid biopsy-based cancer screening tests.

Using an algorithm known as HotNet2, an international team has identified more than a dozen genetically altered sub-networks in thousands of tumor samples assessed for the Cancer Genome Atlas project.

FDA Approves Phase I Study Design for Cellceutix's Anti-Cancer Drug Kevetrin

An expanded license with Dana-Farber Cancer Institute for an offshoot of its Cold-PCR technology allows Transgenomic to develop kits that can detect mutations in common cancer-related genes such as KRAS and P53 directly from blood samples and then analyze the variants using multiple sequencing approaches.

The data, while preliminary, suggests that the drug might require a companion diagnostic to establish p53 status prior to treatment, company officials said.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.